Immatics (IMTX)

• Market cap: $1.3B
• 1 day: 4.62%
• 5 days: 7.46%
• 1 month: -10.45%
• 3 months: -3.26%
• 6 months: -4.13%
• Year to date: -9%
• 1 year: 54.89%
• 5 years: -21.08%
• 10 years: -0.94%
• Sector: Healthcare
• Industry: Biotechnology

About: Immatics NV is a clinical-stage biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.

Employees: 407